LTR Pharma Locks in US Telehealth Deal with 150,000-Unit ROXUS Target

First US Commercial Route for ROXUS Established

LTR Pharma (ASX:LTP) has taken a significant step towards commercialising its rapid-acting intranasal erectile dysfunction treatment, ROXUS, in the United States by signing a binding term sheet with Shed Holdings LLC. This agreement sets a minimum commercial volume target of 150,000 prescription units within the first 12 months following launch, marking the company’s first formal commercialisation framework in the world’s largest ED market.

The deal positions Shed’s Mavrox platform, a US direct-to-consumer telehealth service, as the exclusive channel for ROXUS distribution for two years, subject to ongoing performance metrics including the volume commitment. This exclusivity aims to leverage Shed’s digital patient acquisition and telehealth infrastructure to rapidly scale access to ROXUS, which differentiates itself from traditional oral PDE5 inhibitors through its intranasal, on-demand delivery.

Personalised Medicine Pathway and Supply Chain Setup

ROXUS will be supplied through the US Section 503A personalised medicine pathway, utilising LTR Pharma’s designated 503A pharmacy partner. This route allows for tailored compounding and distribution, aligning with the telehealth model and personalised medicine trends in the US healthcare system.

The term sheet outlines that while the minimum volume and exclusivity provisions are binding, broader commercial terms remain subject to final Definitive Agreements to be negotiated within 60 days. These agreements will also cover onboarding of the pharmacy fulfilment partner and completion of technology transfer and launch-readiness activities.

Strategic Implications for US Market Entry

Executive Chairman Lee Rodne described the agreement as a "defining step" in LTR Pharma’s US commercialisation strategy, highlighting the scalable patient acquisition and telehealth channel as critical to establishing ROXUS in the expanding men’s health market. The performance-based framework with minimum volume targets provides a clear pathway to revenue generation, positioning ROXUS as a potential leader in intranasal ED treatments.

Shed CEO Morley Baker emphasised ROXUS’s differentiation through rapid onset and intranasal delivery, which aligns with consumer demand for flexible and spontaneous treatment options. Shed’s responsibility for platform operations, clinical infrastructure, and marketing costs underlines their commitment to driving uptake.

Next Steps and Market Watchpoints

With the binding term sheet now in place, the focus shifts to completing Definitive Agreements and preparing for commercial launch. The success of this partnership will hinge on Shed meeting the minimum prescription volume and integrating effectively with LTR Pharma’s pharmacy partner.

Given the ongoing clinical development of LTR’s lead intranasal therapies, including SPONTAN® and the pipeline candidate OROFLOW®, this deal could serve as a blueprint for further US commercial expansion. Observers will be watching how the personalised medicine pathway and telehealth distribution model perform in capturing market share within a competitive erectile dysfunction treatment landscape.